The FDA has said repeatedly that it’s committed to fighting the opioid epidemic, and to that end, it approved BioDelivery Sciences’ ($BDSI) Bunavail to treat dependence on the drugs. BioDelivery said it expects to launch the new med late in this year’s third quarter, and its market currently tallies more than two million people in the U.S.

READ FULL ARTICLE Curated publisher From FiercePharma